Biopolym. Cell. 2017; 33(4):256-267.
Structure and Function of Biopolymers
Detection of prostate specific ETS fusion transcripts in cancer samples
1Mevs L. V., 1Gerashchenko G. V., 1Rosenberg E. E., 2Pikul M. V., 2Marynychenko M. V., 3Gryzodub O. P., 3Vozianov S. O., 2Stakhovsky E. A., 1Kashuba V. I.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. National Cancer Institute
    33/43, Lomonosova Str., Kyiv, Ukraine, 03022
  3. State Institution «Institute of Urology of NAMS of Ukraine»
    9-a, Yu. Kotsubyns'koho Str., Kyiv, Ukraine, 04053

Abstract

Aim. To detect ETS fusion transcripts in Ukrainian population and to analyze a possible relationship between the ETS fusion transcripts and clinical characteristics of prostate cancer. Methods. Quantitative PCR (q-PCR) was used to analyze the expression of six fusion transcripts at the mRNA level. The amplified products were analyzed by gel electrophoresis and direct sequencing. We analyzed 37 fresh frozen samples of prostate cancer tissues, 37 paired conventionally normal prostate tissue samples and 20 samples of adenomas. Results. Six ETS fusion transcripts of TMPRSS2 with ERG, ETV1, ETV4, ETV5 were analyzed. Only one out of six fusion ETS transcripts was detected in a cohort of 37 Ukrainian patients with prostate adenocarcinoma. The frequency of detection of the TMPRSS2-ERG fusion transcript in prostate cancer tissues was 56.8 %. The TMPRSS2-ERG expression was also detected in 16 normal prostate tissue samples (43.2 %) and in 4 prostate adenoma samples (20 %). No correlation was found between the frequency of the TMPRSS2-ERG in carcinoma samples and clinical characteristics of the samples. However, an analysis of relative gene expression in all the investigated groups has shown the altered TMPRSS2-ERG expression in some groups with different Gleason scores of prostate adenocarcinoma compared to adenomas and normal tissue samples. The most elevatedTMPRSS2-ERG expression was found in the prostate adenocarcinoma group with the Gleason score > 7. Conclusions. We detected the TMPRSS2-ERG fusion transcript (EF194202.1) in prostate tumor samples as adenocarcinoma (the frequency was 56.8 %) with different Gleason score and some paired normal prostate tissues as adenoma samples in our group of Ukrainian population. The obtained results show that the TMPRSS2-ERG fusion transcript is present at early stages of cancer development. In the further studies we plan to test whether the TMPRSS2-ERG fusion transcript can be used as a diagnostic marker of prostate cancer development.
Keywords: prostate cancer, fusion transcripts, relative gene expression

References

[1] Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497-511.
[2] Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell. 2009;139(6):1069-83.
[3] Luo JH, Liu S, Zuo ZH, Chen R, Tseng GC, Yu YP. Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue. Am J Pathol. 2015;185(7):1834-45.
[4] Feng FY, Brenner JC, Hussain M, Chinnaiyan AM. Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res. 2014;20(17):4442-8.
[5] Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G, Cooper CS. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26(18):2667-73.
[6] Tomlins S et al. Recurrent gene fusions in prostate cancer. United States Patent. 2013; 13: 1–218.
[7] Shtivelman E, Beer TM, Evans CP. Molecular pathways and targets in prostate cancer. Oncotarget. 2014;5(17):7217-59.
[8] Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-8.
[9] Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66(7):3396-400.
[10] Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68(1):73-80. doi: 10.1158/0008-5472.CAN-07-5352.
[11] Krstanoski Z, Vokac NK, Zagorac A, Pospihalj B, Munda M, Dzeroski S, Golouh R. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer. BMC Urol. 2016;16(1):35.
[12] Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol. 2007;20(4):467-73.
[13] Dong J, Xiao L, Sheng L, Xu J, Sun ZQ. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Asian Pac J Cancer Prev. 2014;15(7):3099-103.
[14] Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate. 2006;66(14):1521-34.
[15] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8.
[16] Kochetov AG, Lyang OV, Masenko VP, Zhirov IV, Nakonechnikov SN, Tereshchenko SN. Metody statisticheskoy obrabotki meditsinskikh dannykh: Metodicheskiye rekomendatsii dlya ordinatorov i aspirantov meditsinskikh uchebnykh zavedeniy, nauchnykh rabotnikov. Moskva. 2012; 12.
[17] Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S, Chinnaiyan AM. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res. 2011;71(16):5387-92.
[18] Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009;326(5957):1230.
[19] Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8):668-75.
[20] Meisel Sharon S, Pozniak Y, Geiger T, Werner H. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1. Oncotarget. 2016;7(32):51375-51392. doi: 10.18632/oncotarget.9837.
[21] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995, 57(1): 289–300.
[22] Baker SJ, Reddy EP. Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis. Proc Natl Acad Sci U S A. 2013;110(37):14819-20. 23995446;
[23] Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575-86.
[24] Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22(8):1083-93.